Lung cancer (Amsterdam, Netherlands)HumansAntibodiesMonoclonalHumanizedCarcinoma
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Leonardo Brunetti, David J Pinato, Jarushka Naidoo, Monica Loza, Carlo Genova, Scott Gettinger, So Yeon Kim, Ritujith Jayakrishnan, Talal El Zarif, Marco Russano
Published: 202510.1016/j.lungcan.2025.108799
Abstract
BACKGROUND: The use of first-line single agent immunotherapy in patients with advanced NSCLC and ECOG PS ≥ 2 remains controversial, as this frail population has been largely excluded from pivotal clinical trials. Real-world evidence suggests that alt…
Preview only. Read the full abstract at the source